Enliven Therapeutics (NASDAQ:ELVN) Sets New 12-Month High – Here’s What Happened

Enliven Therapeutics, Inc. (NASDAQ:ELVN) reached a new 52-week high on Tuesday . The stock traded as high as $48.79 and last traded at $48.60, with a volume of 1927396 shares trading hands. The stock had previously closed at $45.96.

Wall Street Analysts Forecast Growth

ELVN has been the topic of several research reports. The Goldman Sachs Group boosted their price target on Enliven Therapeutics from $41.00 to $59.00 and gave the company a “buy” rating in a research note on Friday, May 8th. Wall Street Zen raised Enliven Therapeutics from a “sell” rating to a “hold” rating in a report on Monday, May 11th. Weiss Ratings restated a “sell (d-)” rating on shares of Enliven Therapeutics in a research report on Monday, April 20th. Mizuho upped their target price on Enliven Therapeutics from $45.00 to $62.00 and gave the company an “outperform” rating in a research note on Tuesday, June 2nd. Finally, HC Wainwright upped their target price on Enliven Therapeutics from $48.00 to $56.00 and gave the company a “buy” rating in a research note on Thursday, March 26th. One equities research analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating and one has given a Sell rating to the company. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $63.40.

Enliven Therapeutics Stock Performance

The firm has a market capitalization of $2.97 billion, a price-to-earnings ratio of -29.03 and a beta of 0.29. The firm’s 50-day moving average price is $41.97 and its two-hundred day moving average price is $32.14.

Enliven Therapeutics (NASDAQ:ELVN) last announced its quarterly earnings results on Thursday, May 7th. The company reported ($0.38) EPS for the quarter, topping analysts’ consensus estimates of ($0.44) by $0.06. As a group, equities research analysts anticipate that Enliven Therapeutics, Inc. will post -1.71 EPS for the current year.

Insider Buying and Selling

In related news, Director Lori Anne Kunkel sold 10,000 shares of the firm’s stock in a transaction that occurred on Friday, June 5th. The stock was sold at an average price of $34.54, for a total transaction of $345,400.00. Following the completion of the transaction, the director owned 51,884 shares in the company, valued at $1,792,073.36. This trade represents a 16.16% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Benjamin Hohl sold 6,018 shares of the business’s stock in a transaction on Wednesday, June 17th. The shares were sold at an average price of $43.80, for a total value of $263,588.40. Following the completion of the sale, the chief financial officer directly owned 51,000 shares in the company, valued at approximately $2,233,800. This represents a 10.55% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Corporate insiders own 3.00% of the company’s stock.

Institutional Investors Weigh In On Enliven Therapeutics

Several large investors have recently made changes to their positions in ELVN. KBC Group NV bought a new position in Enliven Therapeutics during the 1st quarter valued at about $38,000. Mirae Asset Global Investments Co. Ltd. grew its stake in Enliven Therapeutics by 25.9% during the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,884 shares of the company’s stock worth $44,000 after buying an additional 594 shares during the last quarter. BNP Paribas Financial Markets increased its holdings in shares of Enliven Therapeutics by 33.3% during the second quarter. BNP Paribas Financial Markets now owns 3,722 shares of the company’s stock worth $75,000 after buying an additional 930 shares in the last quarter. Los Angeles Capital Management LLC acquired a new stake in shares of Enliven Therapeutics during the fourth quarter worth approximately $83,000. Finally, Quantbot Technologies LP raised its stake in shares of Enliven Therapeutics by 47.1% in the second quarter. Quantbot Technologies LP now owns 4,477 shares of the company’s stock valued at $90,000 after acquiring an additional 1,434 shares during the last quarter. Institutional investors own 95.08% of the company’s stock.

About Enliven Therapeutics

Enliven Therapeutics is a clinical-stage biotechnology company focused on developing small-molecule therapies that harness induced proximity mechanisms to selectively target and degrade disease-causing proteins in cancer. Leveraging its proprietary Induced Proximity platform, the company designs molecular glues and related modalities to recruit endogenous cellular machinery for targeted protein degradation, with the goal of treating malignancies driven by so-called “undruggable” oncogenic factors.

The company’s pipeline comprises several early-stage programs directed at key oncogenic drivers across hematologic and solid tumor indications.